Trials
2 active
6 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “A single 100, 200 or 400 μg dose, given as 1, 2 or 4 × 100 μg actuations (exvalve) at 20 second intervals.”In the company’s words, NCT06433921 on ClinicalTrials.gov
- Tested for
- Asthma (2 trials), Mild Asthma
- Main trialPhase 3
- “This study aims to generate additional safety data on the propellant component of the reformulated product by comparing metered dose inhaler (MDIs) containing HFA-152a (test) with HFA-134a (reference).”In the company’s words, NCT07645248 on ClinicalTrials.gov
Other drugs for Asthma
- BenralizumabAstraZeneca · Phase 3
- MM09Inmunotek S.L. · Phase 3
- TEV-56248Teva Branded Pharmaceutical Products R&D, Inc. · Phase 3
- FF/UMEC/VIGSK · Phase 3
- 6103SBio · Phase 3
- DepemokimabGSK · Phase 3
Coming up2
- 28 DecPhase 3 trial completes · ClinicalTrials.gov
- 16 Apr 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Dec 2026 | A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | |
| Phase 1Recruiting | 16 Apr 2027 | A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | |
| Phase 3Completed | 2 Sep 2025 | A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma | |
| Phase 1Completed | 21 May 2023 | Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants | |
| Phase 1Completed | 18 Oct 2024 | A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive | |
| Phase 1Completed | 4 Jun 2025 | A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026